MTAP-DELETED SOLID TUMORS
Clinical trials for MTAP-DELETED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new MTAP-DELETED SOLID TUMORS trials appear
Sign up with your email to follow new studies for MTAP-DELETED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-in-Human trial targets Hard-to-Treat cancers with unique genetic flaw
Disease control Recruiting nowThis study is testing a new oral drug called S095035, both by itself and combined with another drug, for adults with advanced or metastatic solid tumors that have a specific genetic change (homozygous MTAP deletion). The main goals are to find a safe dose and see if the treatment…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New cancer drug PEP08 enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people testing PEP08, a new oral cancer drug, for patients with advanced solid tumors that have a specific genetic change called MTAP deletion. The main goals are to find safe doses, see how the body processes the drug, and look for early signs that it …
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Breakthrough cancer drug targets genetic weakness in tumors
Disease control Recruiting nowThis early-stage clinical trial is testing a new cancer drug called BAY 3713372 in people with advanced solid tumors that have a specific genetic change called MTAP deletion. Researchers want to find the safest dose, understand how the body processes the drug, and see if it can s…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC